Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study

BACKGROUND: The low level of disease activity and manageable safety profile seen with fingolimod versus placebo in a 6-month, phase 2, randomized controlled trial in Japanese patients with relapsing multiple sclerosis (MS; ClinicalTrials.gov Identifier NCT00537082) were maintained in the initial 6-m...

Descripción completa

Detalles Bibliográficos
Autores principales: Saida, Takahiko, Itoyama, Yasuto, Kikuchi, Seiji, Hao, Qi, Kurosawa, Takayoshi, Ueda, Kengo, Auberson, Lixin Zhang, Tsumiyama, Isao, Nagato, Kazuo, Kira, Jun-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5273805/
https://www.ncbi.nlm.nih.gov/pubmed/28129749
http://dx.doi.org/10.1186/s12883-017-0794-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5273805/
https://www.ncbi.nlm.nih.gov/pubmed/28129749
http://dx.doi.org/10.1186/s12883-017-0794-5

Ejemplares similares